Lake Street Reiterates Buy Rating on Vivani Medical, Inc. (VANI)
Lake Street has reiterated its buy rating on Vivani Medical with a price target of $4, a 231.95% upside from the current price.
Key Points
- Lake Street reiterated its buy rating for Vivani Medical, Inc. (VANI) on June 23, 2026, with a price target of $4.
- Lake Street's $4 price target implies 231.95% upside from Vivani Medical, Inc.'s ($VANI) current $1.21 share price.
- Vivani Medical shares traded at $1.18 on Tuesday, with a market cap of $97.4 million and a 52-week range of $0.92 to $1.92.
- Insider Gregg Williams made multiple stock purchases, and analysts' consensus rating remains strong buy with a mean target of $3.75.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Lake Street reiterated its buy rating for Vivani Medical, Inc. (NasdaqCM: VANI) on June 23, 2026. Analyst Thomas Flaten set a price target of $4, reinforcing confidence in the company's future prospects.
Vivani Medical, Inc. Stock Down 15.1%
Shares of NasdaqCM:VANI traded near $1.18 on Tuesday. Vivani Medical, Inc. has a market cap of approximately $97.4 million. The company has a beta of 3.289, indicating higher volatility compared to the market. The stock's 52-week range is between $0.92 and $1.92, with a 50-day moving average of $1.23 and a 200-day moving average of $1.31. The company's current ratio stands at 3.181, with a quick ratio of 3.018 and a debt-to-equity ratio of 95.756.
$VANI price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Vivani Medical, Inc.
Insider Gregg Williams has been actively purchasing shares of Vivani Medical. On June 15, 2026, Williams bought 1,587,301 shares at an average price of $1.26. He made similar purchases on May 15 and April 15, 2026, each time buying the same number of shares at the same price.
Analysts Set New Price Targets
On June 23, 2026, Lake Street reiterated its buy rating for Vivani Medical with a price target of $4. Previously, on April 1, 2026, HC Wainwright & Co. maintained a buy rating with a target of $3.5. The overall analyst consensus for Vivani Medical is a strong buy, with a mean target price of $3.75 based on two analyst opinions.
About Vivani Medical
Vivani Medical, Inc., headquartered in Alameda, California, is a clinical-stage biopharmaceutical company. It focuses on developing miniaturized and subdermal drug implants using its NanoPortal technology. The company aims to improve clinical outcomes in chronic disease treatment. Its product pipeline includes drug implants for chronic weight management and diabetes treatment, with applications in both humans and companion animals. Dr. Adam Mendelsohn, Ph.D., serves as the CEO, leading a team of 42 employees.
Bottom Line
Vivani Medical, Inc. continues to attract attention from analysts and insiders alike. Lake Street's reiterated buy rating and $4 price target highlight ongoing confidence in the company's potential. Investors should note that these ratings are based on past data and may not reflect current market conditions.
Get Vivani Medical, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VANI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.